Do GLP-1 medications help with non-alcoholic fatty liver disease (NAFLD/MASH)?

Yes, GLP-1 medications show significant promise for NAFLD and MASH (metabolic dysfunction-associated steatohepatitis). Semaglutide reduces liver fat content by 30-47% in clinical trials. The mechanism includes direct effects on hepatocytes, improved insulin sensitivity, and weight loss. The FDA granted breakthrough therapy designation for semaglutide in MASH treatment based on phase 2 trial data showing resolution of steatohepatitis without worsening fibrosis. Tirzepatide also demonstrates liver fat reduction. For patients with both obesity and NAFLD/MASH, GLP-1 medications address both conditions simultaneously. Liver enzyme improvements are typically seen within 12-24 weeks of treatment initiation.